機構檔案
組織簡介
病理學科成立於民國五十年八月，是北醫創立甚早、歷史悠久的學科，由本校胡水旺與徐千田創辦人禮聘當時甫自美國哥倫比亞大學學成歸國，時任臺大醫學院副教授之病理界權威陳定堯教授擔任首任主任，並於五十一年八月開始醫學系及牙醫學系的病理學與病理實驗授課，而後陸續開設藥學系、醫技、護理等科系的病理教學。在北醫蓽路藍縷的年代，從零做起，默默耕耘建立北醫病理在教學與醫療服務的美名。陳教授於民國七十六年退休後，由黃德修教授接任學科主任，承繼優良傳統，嘉惠學子。而後繼任的歷任學科主任，皆積極延攬學有專精之優秀人才，秉持以學生為主體，教學為首要目標的使命。
病理學科除學校教學、研究及服務任務外，也負責北醫大三家附屬醫院(附設醫院、萬芳醫院及雙和醫院)所有組織與細胞病理檢查、各項臨床病理討論會、解剖病理專科醫師訓練及實習醫師、實習醫檢生病理實習，實現本校邁向國際一流醫學大學的願景。
指紋
過去五年中的合作和熱門研究領域
概要
-
-
運用中孔洞二氧化矽奈米載體傳遞PBX1抑制劑克服吉西他濱所誘導抗藥性胰臟癌之癌幹細胞特性
Shen, Y.-A. (PI)
1/1/26 → 12/31/26
研究計畫: A - 政府部門 › a - 國衛院
-
探索EGFR/SUCLG2/VEGFA驅動攝護腺癌神經內分泌分化的機制與臨床意義(3/3)
Chen, W.-Y. (PI)
8/1/25 → 7/31/26
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
A calcium-sensing MCTP1/FYN/MEF2C circuit drives therapy-induced neuroendocrine prostate cancer
Dung, P. V. T., Chen, W. Y., Liu, M. K., Yeh, S. D., Kajla, G., Yeh, H. L., Chen, W. H., Jiang, K. C., Li, H. R., Chen, C. S., Beltran, H., Wen, Y. C. & Liu, Y. N., 1月 2026, 於: Neoplasia (United States). 71, 101251.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Analysis of the Yield of Intestinal Metaplasia Based on Biopsy Numbers and Follow-Up Endoscopy in a Large Series of Asian Patients With Barrett's Esophagus
Tsai, Y. N., Chang, C. Y., Chen, C. C., Lee, C. T., Hsu, M. H., Chang, I. W., Lin, J. T., Wang, H. P., Moi, S. H. & Wang, W. L., 1月 2026, 於: Digestive Endoscopy. 38, 1, e70077.研究成果: 雜誌貢獻 › 文章 › 同行評審
1 連結會在新分頁中打開 引文 斯高帕斯（Scopus） -
Critical radiosensitizing parameters of dual-modality gold nanodandelion against cancer radioresistance in MV X-ray and proton therapies
Chuang, Y. C., Chiou, J. F., Wu, P. H., Shen, Y. A., Chang, W. M., Hsia, Y., Kuo, C. C., Wang, W. J., Lo, L. W. & Lee, H. L., 6月 2026, 於: Materials Today Advances. 30, 100757.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取
資料集
-
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
Lin, Y.-C. (Contributor), Wen, K.-C. (Creator), Sung, P.-L. (Contributor), Chou, Y.-T. (Creator), Liew, P.-L. (Contributor), Chen, L.-Y. (Contributor), Huang, R.-L. (Creator), Lai, H.-C. (Contributor) & Chang, L.-T. (Contributor), Figshare, 2020
DOI: 10.6084/m9.figshare.c.5234313.v1, https://springernature.figshare.com/collections/Complete_remission_of_heavily_treated_ovarian_clear_cell_carcinoma_with_ARID1A_mutations_after_pembrolizumab_and_bevacizumab_combination_therapy_a_case_report/5234313/1
資料集: Dataset
-
The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer
Huang, S.-P. (Contributor), Liu, P.-Y. (Contributor), Kuo, C.-J. (Contributor), Chen, C.-L. (Contributor), Lee, W.-J. (Contributor), Tsai, Y.-H. (Creator) & Lin, Y.-F. (Creator), Figshare, 2017
DOI: 10.6084/m9.figshare.c.3794620.v1, https://figshare.com/collections/The_G_h-PLC_1_signaling_axis_drives_metastatic_progression_in_triple-negative_breast_cancer/3794620/1
資料集: Dataset
-
Supplementary Material for: The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme
Lee, P.-Y. (Creator), Chen, C.-L. (Creator), Lin, Z.-Z. (Creator), Cheng, A.-L. (Creator), Chen, E.I.-T. (Creator), Whang-Peng, J. (Creator) & Huang, C.-Y. F. (Contributor), Karger Publishers, 2013
DOI: 10.6084/m9.figshare.5124601.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_The_Aurora_Kinases_Inhibitor_VE-465_is_a_Novel_Treatment_for_Glioblastoma_Multiforme/5124601/1
資料集: Dataset